Research Note: Validation of a low-cost accelerometer to measure physical activity in 30 to 32-d-old male Ross 708 broilers

ABSTRACT: Poultry activity measurements are often associated with expensive equipment or time-consuming behavior observations. Since low-cost accelerometers are available, the current study validated the FitBark (FitBark 2, FitBark Inc., Kansas City, MO) accelerometer for use on 30 to 32-d-old male Ross 708 broilers. The FitBark provides aggregated activity levels based on tri-axial accelerometer technology. Broilers were housed in 5 rooms, each divided into 12 2 × 2.3 m pens (60 birds per pen, 31 kg m−2 final density). From 30 to 32 d, 1 broiler per room (n = 5) was randomly selected and equipped with a 13 g FitBark. Elastic loops were placed around the wings to secure the FitBark medially on the back. During the same time, validity was assessed via ceiling-mounted video cameras. The video recordings were analyzed using 20-min continuous sampling during the photo phase at 8 time periods per bird. Behavior was assessed every second using an ethogram (9,600 data points per bird). In the first step, the FitBark data were matched and correlated with the corresponding video-based observed activity (OA) data. The FitBark and OA data were not normally distributed (1-sample KS test, all n = 800, ZFitBark = 0.21, ZOA = 0.24, all P < 0.001). Therefore, data were transformed, and a repeated measures correlation was performed for each bird, showing a positive correlation between the FitBark and OA data (rrm = 0.76, 95% CI = 0.72−0.78, df = 794, P < 0.001). In the second step, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were calculated. The FitBark correctly identified 91% (sensitivity) of the active and 74% (specificity) of the inactive birds. When the FitBark detected an active or inactive bird, there was a probability of 89% (PPV) and 78% (NPV) that the bird was observed to be active or inactive based on the OA data. Accuracy was at 86%. Overall, FitBark are useful for 1-min interval activity measurements in 30 to 32-d-old male Ross 708 broilers. Further research should focus on validating the FitBark at other ages and in different poultry species

Desquamative gingivitis

Desquamative gingivitis is a clinical finding with several potential etiologies, and therefore histologic examination should be performed to confirm the diagnosis before the implementation of systemic therapy. The best methods for obtaining a mucosal biopsy specimen are discussed to aid the dermatologist in approaching these patients, and indications for additional testing, such as immunofluorescence studies, are reviewed. Desquamative gingivitis is uncommon, and there are no systematic guidelines to assist the physician in treatment, producing a practice gap in management. As such, this article focuses on treatment for individual conditions, with emphasis on levels of evidence. An emphasis is also placed on the role of dental care in disease control and the best methods for achieving good oral hygiene

A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr)

A significant percentage of patients with stage II melanomas suffer a relapse after surgery and therefore need the development of adjuvant therapies. In the study reported here, safety and immunological response were analyzed after vaccination in an adjuvant setting with recombinant modified vaccinia virus Ankara carrying the cDNA for human tyrosinase (MVA-hTyr). A total of 20 patients were included and vaccinated three times at 4-week intervals with 5x10(8) IU of MVA-hTyr each time. The responses to the viral vector, to known HLA class I-restricted tyrosinase peptides, and to dendritic cells transfected with tyrosinase mRNA, were investigated by ELISpot assay on both ex vivo T cells and on T cells stimulated in vitro prior to testing. The delivery of MVA-hTyr was safe and did not cause any side effects above grade 2. A strong response to the viral vector was achieved, indicated by an increase in the frequency of MVA-specific CD4+ and CD8+ T cells and an increase in virus-specific antibody titers. However, no tyrosinase-specific T-cell or antibody response was observed with MVA-hTyr in any of the vaccinated patients. Although MVA-hTyr provides a safe and effective antigen-delivery system, it does not elicit a measurable immune response to its transgene product in patients with stage II melanoma after repeated combined intradermal and subcutaneous vaccination. We presume that modification of the antigen and/or prime-boost vaccination applying different approaches to antigen delivery may be required to induce an effective tyrosinase-specific immune respons